Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NVX 508

Drug Profile

NVX 508

Alternative Names: NVX-508

Latest Information Update: 28 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NuvOx Pharma
  • Class Antianaemics
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vaso-occlusive crisis
  • New Molecular Entity No

Highest Development Phases

  • No development reported Vaso-occlusive crisis

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for preclinical development in Vaso-occlusive-crisis in USA
  • 02 Jul 2020 NVX 508 is still in preclinical development for Vaso-occlusive-crisis in sickle cell disease in USA (NuvOx Pharma pipeline, July 2020)
  • 16 Jul 2018 NuvOx and the University of Pittsburgh withdraws a phase I trial in Vaso-occlusive crisis related to sickle cell anaemia in USA, prior to enrolment (NCT03013426)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top